Effect of Statins and Metformin on Survival in Patients With Non-small Cell Lung Cancer (NSCLC)

SESSION TITLE: Lung Cancer Treatment Posters SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM PURPOSE: Lung cancer is the number one cause of cancer-related death worldwide; with the incidence of NSCLC risen dramatically the importance of understanding the influence of comorbidities and their treatments takes a great importance. The aim of this study was to investigate the effect of statins and metformin on survival in patients (pts) with NSCLC. METHODS: We reviewed the records of all pts diagnosed with NSCLC at our institution from 2011 to 2013. Demographics, comorbidities, statin/ metformin use and survival were analyzed. Cox regression was used for multivariate analysis. RESULTS: A total 205 pts were studied. Median age at diagnosis was 65 years (40-91), there were more males than females (56% vs. 44%). 74% (152) were current or former smokers with average 40 pack years (5-60). The Median BMI was 26.5kg/m2 (18-44), ECOG status was 1 (0-4) and serum creatinine of 1.0 (0.4-3.5). Regarding comorbidities: 48% (98) had hypertension, 45% (93) hyperlipidemia, 22% (44) COPD and 19% (39) diabetes mellitus. At diagnosis, 66% (136) of the pts had stage III/IV disease vs. 25% (69) with stage I/II. Adenocarcinoma was the most common histologic subtype (61%), followed by squamous cell carcinoma (27%). 42% received surgery, 80% systemic chemotherapy and 32% radiation. Median survival was 1320 days (95% CI: 1110-1565). 42% (87) of the pts were receiving statins and 13% (27) metformin. About the statin use, 58% of the pts were taking statins for 25-48 months, 12% for >48 months, 11% for 13-24 months and 18% for less than 12 months. Female gender (OR: 1.98, p<0.001), age<65 years (OR: 0.89, p<0.01) and statin use (OR: 0.78, p<0.02) were independent predictors of survival by multivariate analysis. Metformin use was not a predictor of survival by univariate or multivariate analysis in this group of patients. CONCLUSIONS: In our cohort, almost half of the pts had hypertension and hyperlipidemia. Statin use prior to diagnosis was a significant and positive predictor of survival. In the other hand metformin did not affect the outcome of pts with NSCLC. CLINICAL IMPLICATIONS: Statins are one of the mostly widely prescribed drugs in the US; their proven anti-inflammatory effects may play a role in inhibiting cancer growth. While other observational studies have looked at statins and risk of developing cancer, we specifically looked at the effect of statins on survival in pts on statin therapy prior to cancer diagnosis. More studies are needed to enhance our understanding of the effect of statins on lung cancer. DISCLOSURE: The following authors have nothing to disclose: Narjust Duma, Mohleen Kang, Khaleb Abu-Ihweij, Choudhary Moaz, Maira DosSantos, Arpita Gandhi, Martin Gutierrez No Product/Research Disclosure Information